LYS241
Parkinson's Disease, Stroke, Multiple Sclerosis
Key Facts
About Lys Therapeutics
Lys Therapeutics is a clinical-stage biotech pioneering a novel cytoprotective strategy for neurological disorders by targeting blood-brain barrier dysfunction. Its lead asset, LYS241, is a first-in-class monoclonal antibody that inhibits the pathological tPA-NMDAr interaction on endothelial cells, aiming to halt neuroinflammatory cascades in diseases like Parkinson's, stroke, and multiple sclerosis. The company boasts a strong scientific foundation from the 'Blood and Brain' institute and is led by an experienced team with industry veterans like Michel Vounatsos on its board. Lys is advancing LYS241 through preclinical and early clinical development with formulations for both acute and chronic administration.
View full company profile